# RxVigilance Mobile

> Offline medical reference for healthcare professionals with drug info, travel health, and natural products. (iPhone/iPad app by Vigilance Sante Inc..)

- Source: https://appshunter.io/ios/app/rxvigilance-mobile/id1166663774 (this page in markdown: same URL + `.md`)
- Developer: [Vigilance Sante Inc.](https://appshunter.io/developer/1166663773)
- Category: Medical, Health & Fitness
- Price: Free with in-app purchases
- Age rating: 17+
- Requires: iOS 11.0 · 88 MB
- Languages: English, French
- Released: 2016-11-01
- Data updated: 2026-06-10
- Monetization: free
- User reviews in markdown: https://appshunter.io/ios/app/rxvigilance-mobile/id1166663774/reviews.md

## What is RxVigilance Mobile?

RxVigilance - a reference tool for health care professionals that features information on drugs and health - can now be accessed from anywhere.

After installation, THE APPLICATION RESIDES ENTIRELY ON THE DEVICE and does not require an Internet connection for regular use. Internet access is required for updates.

Already used by thousands of physicians, pharmacists, nurses and other health care professionals across Canada, RxVigilance provides you with relevant and up to date information from several dozen leading reference sources. Drug monographs, pharmacological profile analysis, and information on natural products and travel destinations are among some of the many features you can now access through your device. 

Our team of health care professionals is well aware of your day to day information needs. As a result, they are equipped to select what is most useful and relevant for you and your practice and to integrate that information to RxVigilance. In short, you will be able to access what you need quickly and effectively.

The RxVigilance Mobile App includes access to: 

COMPARATIVE CHARTS
In the application users will find a series of charts comparing the characteristics of products from the same pharmacological class in order to help them make the best therapeutic decision based on onset of action or the number of administrations a day, for example.

MONOGRAPHS
Professional information on more than 1200 drugs. You can find information on adverse reactions, official and unofficial indications, adult dosages, pediatric dosages, geriatric dosages, adjustments for renal and hepatic impairment, precautions in pregnancy/breastfeeding, special precautions (grapefruit, stability, food, etc.), contraindications, interactions and kinetics. Monographs are regularly updated with information deemed relevant by our team of professionals.

TRAVEL
This feature allows to search for over 200 destinations. It provides access to brief and relevant overview of the destination (currency, languages, population, capital), required and/or recommended immunizations by country, recommendations based on diseases found in each country and contact details for service centres that may be of use while traveling.

NATURAL PRODUCTS
Information on more than 60 of the most commonly used natural products. It includes product indications (classified by evidence of effectiveness), product description and discussion on product safety and efficacy.

PROFILE ANALYSIS
Profile analysis allows to identify interactions and provides a description of the interactions as well as recommendations. Interactions are classified by importance of actions to be taken by the professional.

BULLETINS
Monthly communiqué for subscribers with details on the most recent updates and new developments and a list of monographs to which changes have been made. It is possible to refer to bulletins from prior months and send questions or comments via e-mail to the Rx Vigilance team.

PHONE DIRECTORY
A phone directory that consists of over 6000 useful contacts such as: hospitals, CLSCs, support groups and self-help groups, pharmacies, pharmaceutical companies, etc. It allows users to dial phone numbers directly from their iPhone and to acces links to internet sites when available.

## Key features

- Drug monographs
- Comparative charts
- Travel health information
- Natural product details
- Profile analysis for interactions
- Monthly bulletins

## Pricing and in-app purchases

Base price: Free.

**One-time purchases**

| Purchase | Price | Type |
| --- | --- | --- |
| Subscription renewal | $169.99 | one-time |


## Recent user reviews (9 of 9)

All indexed reviews: https://appshunter.io/ios/app/rxvigilance-mobile/id1166663774/reviews.md

### 2/5 — Touch screen ne répond pas.

*2025-02-19, version 2.0.117*

Bug persistant du touch screen rendant impossible de sélectionner le 1er item. Je dois constamment réinstaller l’app pour que ça fonctionne.

### 1/5 — Comment s’inscrire ? Application installée mais impossible d avoir une inscription Merci

*2024-11-15, version 2.0.114*

???

### 1/5 — Informations incompletes

*2022-03-21, version 2.0.80*

L’usage de l’application est tres limitée et les informations sont incompletes. Toutes les interactions ne sont pas indiquées. Je ne recommande pas l’application pour usage professionel car l’analyse des interactions est des informations est incomplete et s’avere donc faux et dangereux

### 2/5 — Opening the app is too long

*2021-01-16, version 2.0.66*

Openinh the app each time takes 10 sec, there’s a image download, its too long , please fix that

### 1/5 — Ne fonctionne plus

*2020-09-10, version 2.0.62*

Connexion impossible depuis la dernière mise à jour, ne reconnaît malheureusement plus mon compte

### 1/5 — Mise à jour

*2020-06-09, version 2.0.5.8*

L’application ne fonctionne plus depuis la dernière mise à jour.

### 4/5 — Drug coverage and annex

*2020-03-23, version 2.0.55*

I think you should add drug coverage and the annex i think it’s a good part off your product

### 5/5 — Best App for Pharmacists

*2018-06-21, version 2.0.31*

User friendly, info is found quickly which is ideal for professionals working in a fast pace environment.

### 1/5 — doesnt work

*2016-11-09, version 2.0.0*

tried to renew subscription. click renew button but nothing happens

## Frequently asked questions about RxVigilance Mobile

### What is RxVigilance Mobile?

RxVigilance Mobile is a medical reference tool designed for healthcare professionals. It provides offline access to extensive information on drugs, natural products, and travel health, helping users make informed decisions.

### Does RxVigilance Mobile require an internet connection?

No, the application resides entirely on the device and does not require an internet connection for regular use. Internet access is only needed for updates.

### What kind of drug information does RxVigilance Mobile offer?

RxVigilance Mobile provides professional information on over 1200 drugs, including adverse reactions, indications, dosages, precautions, interactions, and kinetics. Monographs are regularly updated by a team of healthcare professionals.

### Can RxVigilance Mobile help with travel health?

Yes, the app includes a travel feature that offers over 200 destinations. It provides overviews, immunization recommendations, disease-based advice, and contact details for service centers.

### What are the age restrictions for RxVigilance Mobile?

RxVigilance Mobile has an age rating of 17+, making it suitable for adult healthcare professionals.

### On which devices can I use RxVigilance Mobile?

RxVigilance Mobile is available for iPhone, iPad, and iPod devices, ensuring accessibility for a wide range of Apple users.

### How often is RxVigilance Mobile updated?

The app was last updated on February 28, 2025, with version 2.0.118. Subscribers receive monthly bulletins detailing recent updates and changes to monographs.

### Does RxVigilance Mobile contain advertisements?

No, RxVigilance Mobile is ad-free. As indicated by the 'hasAds' flag being false, users can expect an uninterrupted experience without advertisements.

## Version history (last 5 releases)

### 2.0.118 — 2025-02-28

March 2025
(monthly update)

New monographs
=========================
Fezolinetant (Veozah)
Iptacopan (Fabhalta)
Perfluorohexyloctane (Miebo)

### 2.0.117 — 2025-01-27

February 2025
(monthly update)

Modifications to RxVigilance
=========================
Perioperative management of direct oral anticoagulants

We have updated the Perioperative management section of our comparative chart of oral anticoagulants to include the most recent recommendations on discontinuing and resuming direct oral anticoagulants (DOACs), as well as on assessing both thromboembolic and bleeding risks. This update takes into account the latest clinical advances and offers a clearer organization of the information related to perioperative patient management.

New Section: Postexposure Prophylaxis-in-Pocket (PIP)

We have updated our comparative chart on antiretrovirals for HIV infection by adding a section on Postexposure prophylaxis-in-pocket (PIP). This approach consists in providing the patient with a prescription for postexposure prophylaxis before they need it, so that they have immediate access to the medication in the event of potential HIV exposure.

QT interval

The list of medications that can prolong the QT interval has been revised based on updated data from CredibleMeds. Levetiracetam has thus been removed to the list entitled Possible risk of torsades de pointes. 

New monographs
=========================
Danicopan (Voydeya)
Avapritinib (Ayvakyt)
Ruxolitinib topical (Opzelura)

### 2.0.116 — 2024-12-16

January 2025
(monthly update)

New monographs
=========================
Momelotinib (Ojjaara)
Fruquintinib (Fruzaqla)
Olipudase alfa (Xenpozyme)

### 2.0.115 — 2024-11-20

December 2024
(monthly update)

Modifications to RxVigilance
=========================
Adjustments in dialysis

We have enhanced our monographs with a new section dedicated to dose adjustments for patients on hemodialysis and peritoneal dialysis. This addition complements the existing information on renal impairment and dialysis supplements, providing you with even more precise and tailored recommendations for these clinical situations.
You will see the Adjustment in dialysis section gradually appear in our monographs, located just below the Renal impairment section.



New monographs
=========================
Lebrikizumab (Ebglyss)

### 2.0.114 — 2024-11-08

November 2024
(monthly update)

Modifications to RxVigilance
=========================
Antidepressants

Our antidepressants comparative drug chart has been updated to reflect the latest data on depression, notably CANMAT's new clinical guidelines for the management of major depressive disorder in adults. 
As well as a comparison of different antidepressants, you'll find a wealth of relevant information on topics such as treatment goals, follow-up therapy, switching from one antidepressant to another, and treatment of specific populations


New monographs
=========================
Sotatercept (Winrevair)
Clindamycin + benzoyl-peroxide + adapalene (Cabtreo)
Cholera vaccine (Vaxchora)
Chikungunya vaccine (Ixchiq)
Vorasidenib (Vorangio)

## Apps similar to RxVigilance Mobile

| App | Rating | Price | Category |
| --- | --- | --- | --- |
| [Antibiothérapie Pédiatrique](https://appshunter.io/ios/app/antibiotherapie-pediatrique/id1302793888) | — | Free | Medical |
| [Dog Symptom Checker](https://appshunter.io/ios/app/dog-symptom-checker/id392537780) | 1.0 (1) | $2.99 | Medical |
| [USPSTF Prevention TaskForce](https://appshunter.io/ios/app/uspstf-prevention-taskforce/id311852560) | 3.6 (68) | Free | Medical |
| [Hypnosis for Childbirth](https://appshunter.io/ios/app/hypnosis-for-childbirth/id477599840) | 5.0 (1) | $4.99 | Medical |
| [Lanthier](https://appshunter.io/ios/app/lanthier/id701664895) | 3.8 (5) | Free | Medical |
| [CCL eLab Community](https://appshunter.io/ios/app/ccl-elab-community/id492766180) | — | Free | Medical |

## More apps by Vigilance Sante Inc.

- [RxVigilance](https://appshunter.io/ios/app/rxvigilance/id6741224580)

All apps by Vigilance Sante Inc.: https://appshunter.io/developer/1166663773

---

*Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-06-10.*
